Results 21 to 30 of about 53,742 (236)

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]

, 2012
The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco, Aldea, Ana, Alonso-Navarro, Hortensia, Bernal, María Luisa, Borobia, Alberto M., Borràs, Emma, Carballo, Miguel, Carvajal, Alfonso, García-Agúndez, José Augusto, García-Martín, Elena, García-Muñiz, José D., Gervasini, Guillermo, Jiménez-Jiménez, Félix Javier, Lucena, María Isabel, Martínez, Carmen, Sacristán, José A., Salado, Inés, Sinués, Blanca, Vicente, Jorge   +18 more
core   +4 more sources

Pharmacogenomics

, 2023
Pharmacogenomics is an emerging field that investigates how a person's unique genetic makeup affects their response to medications. By analyzing genetic variations, researchers can identify genetic markers that influence drug metabolism, efficacy, and adverse effects.
openaire   +1 more source

Cancer Pharmacogenomics [PDF]

Clinical Pharmacology & Therapeutics, 2011
Pharmacogenomics research is yielding molecular diagnostic tools that can be used to optimize the selection of medications and their doses for individual patients. Given the narrow therapeutic index of most anticancer agents and the serious consequences of undertreatment, cancer chemotherapy is a compelling therapeutic area for translation of ...
S. W. Paugh, STOCCO, GABRIELE, J. R. McCorkle, B. Diouf, K. R. Crews, W. E. Evans   +5 more
openaire   +3 more sources

Cannabis Pharmacogenomics: A Path to Personalized Medicine

Current Issues in Molecular Biology, 2023
Cannabis and related compounds have created significant research interest as a promising therapy in many disorders. However, the individual therapeutic effects of cannabinoids and the incidence of side effects are still difficult to determine ...
Mariana Babayeva, Zvi G. Loewy
doaj   +1 more source

Clinical application of high throughput molecular screening techniques for pharmacogenomics. [PDF]

, 2011
Genetic analysis is one of the fastest-growing areas of clinical diagnostics. Fortunately, as our knowledge of clinically relevant genetic variants rapidly expands, so does our ability to detect these variants in patient samples.
Schrijver, Iris, Wiita, Arun P
core   +1 more source

Physicians’ pharmacogenomics information needs and seeking behavior: a study with case vignettes

BMC Medical Informatics and Decision Making, 2017
Background Genetic testing, especially in pharmacogenomics, can have a major impact on patient care. However, most physicians do not feel that they have sufficient knowledge to apply pharmacogenomics to patient care. Online information resources can help
Bret S. E. Heale, Aly Khalifa, Bryan L. Stone, Scott Nelson, Guilherme Del Fiol   +4 more
doaj   +1 more source

Role of Esrrg in the Fibrate-Mediated Regulation of Lipid Metabolism Genes in Human ApoA-I Transgenic Mice [PDF]

, 2009
We have used a new ApoA-I transgenic mouse model to identify by global gene expression profiling, candidate genes that affect lipid and lipoprotein metabolism in response to fenofibrate treatment.
A Chroni, A Duka, A Patsialou, A Rigotti, A Walsh, AP Feinberg, B Staels, B Staels, B Staels, B Staels, B Staels, B Staels, BN Finck, CW Miller, D Arsenijevic, D Lan, D Sanoudou, D Sanoudou, D Sanoudou, EM Rubin, ES Cathcart, F Yadetie, G Fredrikson, G Martin, H Duez, H Samyn, HB Rubins, HY Kan, J Karbowska, J Lin, J St Pierre, JC Fruchart, JD Brunzell, JJ Lehman, JK Reddy, JL Goldstein, JM Huss, JM Huss, JP Desager, K C Hayes, K Drosatos, K Motojima, K Schoonjans, K Schoonjans, KE Kypreos, KE Kypreos, KS Frederiksen, L Berthou, LA Pennacchio, LJ Kelly, M Bouly, MB Eisen, MC Hunt, MJ Holness, N Hennuyer, N Vu-Dac, N Vu-Dac, N Vu-Dac, N Vu-Dac, NF Cariello, P Puigserver, Q Guo, R Sladek, RB Vega, RL Jacobs, SA Greenberg, SN Schreiber, V Beisvag, V Giguere, V I Zannis, V Litvak, VG Tusher, VI Zannis, VI Zannis, VI Zannis, WC Roberts, X Prieur, Y Kamei, Y Nagai, Z Wu   +79 more
core   +3 more sources

Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow

Frontiers in Pharmacology, 2019
Pharmacogenomics has been recognized as a fundamental tool in the era of personalized medicine with up to 266 drug labels, approved by major regulatory bodies, currently containing pharmacogenomics information. Next-generation sequencing analysis assumes
Efstathia Giannopoulou, Theodora Katsila, Christina Mitropoulou, Evangelia-Eirini Tsermpini, George P. Patrinos, George P. Patrinos, George P. Patrinos   +6 more
doaj   +1 more source

Cancer Clinical Trials Optimization and Pharmacogenomics [PDF]

, 2012
A critical overview of recent clinical trials in cancer is presented focused on signaling pathways blockers or inhibitors with a view to developing successful clinical trials employing personalized cancer therapies.
I. C. Baianu
core   +2 more sources

Distinct expression profiles and functions of Kindlins in breast cancer

Journal of Experimental & Clinical Cancer Research, 2018
Background Kindlin-1, − 2, and − 3 are the three members of the Kindlin family. They are best known as regulators of integrin functions, contributing to fundamental biological processes such as cell survival, adhesion and migration.
Paula Azorin, Florian Bonin, Ahmad Moukachar, Aurélie Ponceau, Sophie Vacher, Ivan Bièche, Elisabetta Marangoni, Laetitia Fuhrmann, Anne Vincent-Salomon, Rosette Lidereau, Keltouma Driouch   +10 more
doaj   +1 more source